Therapeutic Applications of CRISPR-Cas9 Gene Editing

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

CRISPR-Cas9 is a gene editing tool used extensively in biological research that is now making3 its way into clinical therapies. With the first CRISPR therapy obtaining approval by the United4 States’ Food and Drug Administration (FDA) in late 2023, we look at clinical trials of emerging5 therapies involving CRISPR-Cas9, currently the most prevalent CRISPR-based tool in these6 trials. A CRISPR-based therapy is currently approved for treatment of both sickle-cell anemia and7 transfusion-dependent β-thalassemia but clinical trials for CRISPR-based therapeutics include a8 much broader range of targets. CRISPR-Cas9 is being explored to treat cancer, infectious disease,9 and more. This review highlights CRISPR-Cas9 clinical trials registered at clinicaltrials.gov as of10 12/31/2024.

Article activity feed